BioSpace News Archive

FDA

Arrowhead Pharmaceuticals Receives Orphan Drug Designation for ARO-ANG3

Arrowhead Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration has granted orphan drug designation to ARO-ANG3 for the treatment of homozygous familial hypercholesterolemia.

July 16, 2019
·
4 min read
Pharm Country

Inovio Sharpens Focus On HPV-Related Diseases And Fast-to-Market Product Candidates

Inovio Pharmaceuticals, Inc. announced that it has sharpened its corporate strategy to focus on the commercial development of its late-stage HPV assets and reallocate capital to develop fast-to-market product candidates.

July 16, 2019
·
7 min read
Drug Development

Tradipitant Effective in Preventing Motion Sickness

Vanda Pharmaceuticals Inc. announced that tradipitant, a neurokinin-1 receptor antagonist, was effective in treating motion sickness in a clinical study conducted in the Pacific Ocean.

July 16, 2019
·
7 min read
Deals

Charles River Laboratories Schedules Second-Quarter 2019 Earnings Release and Conference Call

Charles River Laboratories International, Inc. will release second-quarter 2019 financial results on Wednesday, July 31st, before the market opens.

July 16, 2019
·
1 min read
Deals

Senseonics Announces Commencement of Convertible Notes Offering

Senseonics Holdings, Inc. announced the commencement of an offering of $80.0 million aggregate principal amount of 5.25% convertible senior notes due 2025 and the commencement of a consent solicitation in respect of its outstanding 5.25% convertible senior subordinated notes due 2023.

July 16, 2019
·
7 min read
Policy

Altaire Pharmaceuticals, Inc. Issues Voluntary Recall Of Over-The-Counter Ophthalmic Products Sold By Natural Ophthalmics And TRP Company, Inc.

Altaire Pharmaceuticals, Inc., announces that it is voluntarily recalling the Over-the-Counter drug products and lots, within expiry, sold by Natural Ophthalmics and TRP Company, Inc.

July 16, 2019
·
4 min read
Biotech Beach

NextGen Healthcare Partners with Appriss Health to Combat Substance Use Disorder

Enhanced prescription capabilities in NextGen Office will help prevent the illegal acquisition of controlled substances from multiple sources

July 16, 2019
·
4 min read
Drug Development

Mallinckrodt Halts Phase 2B Trial Investigating the Use of Acthar® Gel (Repository Corticotropin Injection) in Amyotrophic Lateral Sclerosis (ALS)

Mallinckrodt plc announced that it is permanently discontinuing its Phase 2B study designed to assess the efficacy and safety of Acthar® Gel as an investigational treatment for amyotrophic lateral sclerosis.

July 16, 2019
·
11 min read
Deals

Chardan Healthcare Acquisition Corp. Announces Merger Agreement with BiomX Ltd.

Chardan Healthcare Acquisition Corp. announced that it has entered into a definitive agreement for a business combination with BiomX Ltd., a microbiome company developing both natural and engineered phage therapies.

July 16, 2019
·
13 min read
Deals

UAVenture Capital Fund Invests in Automatic Eyeglass Prescription Technology

UAVenture Capital Fund announced its seventh portfolio investment and the second investment from Fund II.

July 16, 2019
·
2 min read